Sage Therapeutics, Inc.
SAGE
$7.97
$0.1051.34%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 7.96% | 37.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.96% | 37.17% | |||
| Cost of Revenue | 1.30% | -15.01% | |||
| Gross Profit | 0.56% | 23.17% | |||
| SG&A Expenses | 2.68% | -4.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.61% | -5.74% | |||
| Operating Income | 20.61% | 9.07% | |||
| Income Before Tax | -2.38% | 9.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.38% | 9.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.38% | 9.04% | |||
| EBIT | 20.61% | 9.07% | |||
| EBITDA | 20.54% | 9.05% | |||
| EPS Basic | -2.14% | 9.91% | |||
| Normalized Basic EPS | 21.17% | 9.91% | |||
| EPS Diluted | -2.14% | 9.91% | |||
| Normalized Diluted EPS | 21.17% | 9.91% | |||
| Average Basic Shares Outstanding | 0.24% | 0.96% | |||
| Average Diluted Shares Outstanding | 0.24% | 0.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
